Vol 46, No 2 (2015)
Prace poglądowe / Reviews
Published online: 2015-04-01

open access

Page views 191
Article views/downloads 416
Get Citation

Connect on Social Media

Connect on Social Media

Acute myeloid leukemia – treatment of relapsed and refractory form

Beata Piątkowska-Jakubas, Agnieszka Sporek-Kunicka1
DOI: 10.1016/j.achaem.2015.02.007
Acta Haematol Pol 2015;46(2):121-127.


Relapsed and refractory acute myeloid leukemia (AML) is defined by clinical and biologic features that predict their poor response to therapy. Despite even the most aggressive and well-developed strategies for treatment, most patients succumb to the disease. No currently available treatment has demonstrated consistent efficacy in terms of salvage therapy or long-term survival in this group of patients. This review will discuss some of the emerging strategies: targeted molecular therapies, novel cytotoxics, and immune-based therapies to treat relapsed and refractory AML patients.

Article available in PDF format

View PDF (Polish) Download PDF file